Format

Send to

Choose Destination
Rev Panam Salud Publica. 2013 Jun;33(6):414-21.

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.

Author information

1
Hospital Para el Niño Poblano, Puebla, Mexico. marycrunch@hotmail.com

Abstract

OBJECTIVE:

To assess the safety and immune responses induced by a 13-valent pneumococcal conjugate vaccine (PCV13) after immunization of infants in Mexico.

METHODS:

PCV13 was given with other routine childhood vaccinations to 225 infants in Mexico at ages 2, 4, 6, and 12 months.

RESULTS:

The proportions of subjects achieving immunoglobulin G (IgG) concentrations ≥0.35 µg/mL after the infant series and toddler dose were ≥93.1% and ≥96.7%, respectively, for all 13 serotypes. The serotype-specific pneumococcal IgG geometric mean concentrations after the infant series and toddler dose ranged from 1.18 to 9.13 µg/mL and from 1.62 to 15.41 µg/mL, respectively. The most common local reaction and systemic event after each dose were tenderness and irritability, respectively. Most fever was mild; no fever >40.0°C (i.e., severe) was reported. One subject withdrew because of Kawasaki disease 5 days after the first dose of vaccines, but this condition was not considered related to PCV13.

CONCLUSIONS:

Overall, PCV13 administered with routine pediatric vaccines was immunogenic and safe in healthy infants in Mexico.

PMID:
23939366
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center